Ascendis Pharma A (ASND) Short term Debt (2021 - 2026)

Ascendis Pharma A has disclosed Short term Debt across 6 years of filings, most recently posting $340.1 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $340.1 million, up 85.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $340.1 million (up 85.19% YoY), and the FY2025 annual result was $298.3 million, up 85.25% from the prior year.
• Short term Debt came in at $340.1 million for Q1 2026 at Ascendis Pharma A, up from $298.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $340.1 million in Q1 2026 to a low of $94.1 million in Q2 2023.
• The 5-year median for Short term Debt is $161.1 million (2022), against an average of $180.9 million.
• Across the five-year window, Short term Debt jumped 1913.83% in 2022 and retreated 24.07% in 2023, its largest moves.
• Ascendis Pharma A's Short term Debt stood at $161.1 million in 2022, then dropped by 4.33% to $154.2 million in 2023, then grew by 4.43% to $161.0 million in 2024, then jumped by 85.25% to $298.3 million in 2025, then climbed by 14.02% to $340.1 million in 2026.
• The last three Short term Debt figures came in at $340.1 million (Q1 2026), $298.3 million (Q4 2025), and $273.3 million (Q3 2025), per Business Quant data.